Compare Cassava Sciences Inc (FLNA) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hormel Foods Corp — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Hormel Foods Corp trades at $19.44 (market cap $10.69B). The key difference: Hormel Foods Corp is far larger — about 271.3× Cassava Sciences Inc's market cap, and Hormel Foods Corp pays a 6.02% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Hormel Foods Corp for 99 Days on average.
| FLNA | HRL | |
|---|---|---|
Market Cap | $39.40M | $10.69B |
Volume | 759,018 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $26.50 |
52-Week Low | $0.68 | $19.42 |
Typical Hold Time | 37 Days | 99 Days |
Enterprise Value | -$43.28M | $12.67B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Hormel Foods (HRL) trades at $19.55, down 1.66% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 2.82% for 2025, with recent quarterly EPS beats but a year-over-year decline in net income. Its acquisition of Brakebush for $1.06 billion aims to expand its foodservice chicken business, while the dividend yield remains a key attraction as a Dividend King.
The stock presents a mixed outlook: analyst consensus targets $24.25 imply upside, but high P/E of 31.53 and shrinking profit margins pose valuation and growth concerns. Risks include execution on acquisitions and consumer spending pressures, yet the strong dividend history offers income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
